ADT
60
-9
SEE
52
-3
LLY
57
-2
SPG
48
-3
T
68
5
PNC
63
-2
VTR
46
2
AMAT
59
4
DNB
38
-4
KMI
50
4
EMC
84
-5
WAT
59
-2
DRI
60
-3
HD
47
-3
MTCH
68
2
WMT
60
-6
EQR
31
-2
AA
34
6
RIG
38
3
OKE
55
3
ADT
60
-9
SEE
52
-3
LLY
57
-2
SPG
48
-3
T
68
5
PNC
63
-2
VTR
46
2
AMAT
59
4
DNB
38
-4
KMI
50
4
EMC
84
-5
WAT
59
-2
DRI
60
-3
HD
47
-3
MTCH
68
2
WMT
60
-6
EQR
31
-2
AA
34
6
RIG
38
3
OKE
55
3
Financhill
Back

Reshape Lifesciences 10K Form

Sell
16

RSLS
Reshape Lifesciences

Last Price:
$4.17
Seasonality Move:
-31.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RSLS News And Ratings

See the #1 stock for the next 7 days that we like better than RSLS

RSLS Financial Statistics

Sales & Book Value

Annual Sales: $8M
Cash Flow: $-2.1M
Price / Cash Flow: 0
Annual Sales: $9.24
Price / Book: 2.55

Profitability

EPS (TTM): 262.50000
Net Income (TTM): $-3.5M
Gross Margin: $5.1M
Return on Equity: -172.58%
Return on Assets: -54.94%

Reshape Lifesciences Earnings Forecast

Key Reshape Lifesciences Financial Ratios

  • The Gross Profit Margin over the past 17 years for RSLS is 63.17%.
  • The Selling, General & Administrative Expenses for RSLS have been equal to 123.93% of Gross Profit Margin.
  • The Research & Development expenses have been 22.52% of Revenue.
  • The Net Earning history of RSLS is -89.06% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 13 years.

Reshape Lifesciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: RSLS
CUSIP: 761123
Website: reshapelifesciences.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.53
Quick Ratio: 0.79

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RSLS Technical Analysis vs Fundamental Analysis

Sell
16
Reshape Lifesciences (RSLS) is a Sell

Is Reshape Lifesciences a Buy or a Sell?